Clinical trial
Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled…
NCT00429377 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00429377 |
|---|---|
| Title | Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study |
| Official title | Phase 3 Study of Tacrolimus(FK506)for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Nephritis |
| Intervention type | Drug |
| Interventions | tacrolimus |
| Enrollment | 64 |
| Start date | Jun 1, 2003 |
| First posted | Jan 31, 2007 |
| Last update posted | Jan 31, 2007 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: